About Beijing Jiakesi drug development
Beijing Jiakesi drug development is a company based in Beijing (China) founded in 2015.. Beijing Jiakesi drug development has raised $55 million across 3 funding rounds from investors including Qiming Venture Partners, Lilly Asia Ventures and Prudence Investment Management. The company has 257 employees as of December 31, 2024. Beijing Jiakesi drug development operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.
- Headquarter Beijing, China
- Employees 257 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Jacobio Pharmaceuticals Group Co., Ltd.
-
Annual Revenue
$21.74 M (USD)140.52as on Dec 31, 2024
-
Net Profit
$-21.74 M (USD)57.46as on Dec 31, 2024
-
EBITDA
$-26.67 M (USD)52.01as on Dec 31, 2024
-
Total Equity Funding
$55 M (USD)
in 3 rounds
-
Latest Funding Round
$55 M (USD), Series C
Aug 30, 2018
-
Investors
Qiming Venture Partners
& 3 more
-
Employee Count
257
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beijing Jiakesi drug development
Beijing Jiakesi drug development is a publicly listed company on the HKEX with ticker symbol 1167 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Beijing Jiakesi drug development
Beijing Jiakesi drug development has successfully raised a total of $55M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in August 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $55.0M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2018 | Amount | Series C - Beijing Jiakesi drug development | Valuation | Qiming Venture Partners , Hillhouse | |
| Jun, 2017 | Amount | Series B - Beijing Jiakesi drug development | Valuation | Lilly Asia Ventures , Qiming Venture Partners |
|
| Feb, 2016 | Amount | Series A - Beijing Jiakesi drug development | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Beijing Jiakesi drug development
Beijing Jiakesi drug development has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiming Venture Partners, Lilly Asia Ventures and Prudence Investment Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Global private equity investments are managed with long-term focus.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Beijing Jiakesi drug development
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Beijing Jiakesi drug development
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Beijing Jiakesi Drug Development Comparisons
Competitors of Beijing Jiakesi drug development
Beijing Jiakesi drug development operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Beijing Jiakesi Drug Development
Frequently Asked Questions about Beijing Jiakesi drug development
When was Beijing Jiakesi drug development founded?
Beijing Jiakesi drug development was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Beijing Jiakesi drug development located?
Beijing Jiakesi drug development is headquartered in Beijing, China.
Is Beijing Jiakesi drug development a funded company?
Beijing Jiakesi drug development is a funded company, having raised a total of $55M across 3 funding rounds to date.
How many employees does Beijing Jiakesi drug development have?
As of Dec 31, 2024, the latest employee count at Beijing Jiakesi drug development is 257.
What is the annual revenue of Beijing Jiakesi drug development?
Annual revenue of Beijing Jiakesi drug development is $21.74M as on Dec 31, 2024.
What does Beijing Jiakesi drug development do?
Beijing Jiakesi was established in 2015 in Beijing, China, within the pharmaceutical sector focused on oncology. Small molecule-based therapeutics targeting cancer are developed by the company. The lead candidate, JAB-3068, is currently in Phase 1 clinical trials as an anti-tumor agent. Additional candidates, including JAB-3000, JAB-6000, and JAB-8000, remain in pre-clinical development stages. Operations center on advancing these compounds for potential cancer therapies.
Who are the top competitors of Beijing Jiakesi drug development?
Beijing Jiakesi drug development's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
Is Beijing Jiakesi drug development publicly traded?
Yes, Beijing Jiakesi drug development is publicly traded on HKEX under the ticker symbol 1167.
Who are Beijing Jiakesi drug development's investors?
Beijing Jiakesi drug development has 4 investors. Key investors include Qiming Venture Partners, Lilly Asia Ventures, Prudence Investment Management, and Hillhouse.
What is Beijing Jiakesi drug development's ticker symbol?
The ticker symbol of Beijing Jiakesi drug development is 1167 on HKEX.